NuvaRing

U.S. stocks rallied for the second straight day, ending a tumultuous week on a positive note as investors found more positives than negatives in today's job reports. "It was bad, but not that bad," an investment officer at Wells Fargo told CNBC. "We've made some progress here, we still think we...

Merck (NYSE: MRK) is suing Actavis (NYSE: ACT) in an attempt to keep a generic version of its profitable NuvaRing birth control device off the market, Bloomberg reported. Merck is accusing Warner Chilcott, a division of Actavis, of violating its patent on NuvaRing. Actavis has announced that it...